Literature DB >> 20967172

Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Massimo Franchini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20967172      PMCID： PMC2957496          DOI： 10.2450/2010.0067-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  46 in total

1.  Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.

Authors:  Frédérique Orsini; Chantal Rotschild; Philippe Beurrier; Albert Faradji; Jenny Goudemand; Benoît Polack
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

Review 2.  Overview of inhibitors.

Authors:  Jan Astermark
Journal:  Semin Hematol       Date:  2006-04       Impact factor: 3.851

3.  Immune tolerance and the immune modulation protocol.

Authors:  E Berntorp; I M Nilsson
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

4.  High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products.

Authors:  E Briët; F R Rosendaal; W Kreuz; V Rasi; K Peerlinck; J Vermylen; R Ljung; A Rocino; J Addiego; J I Lorenzo
Journal:  Thromb Haemost       Date:  1994-07       Impact factor: 5.249

Review 5.  Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Authors:  I Scharrer; G L Bray; O Neutzling
Journal:  Haemophilia       Date:  1999-05       Impact factor: 4.287

6.  Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.

Authors:  A R Giles; G E Rivard; J Teitel; I Walker
Journal:  Transfus Sci       Date:  1998-06

7.  Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.

Authors:  Wolfhart Kreuz; Joan C Gill; Chantal Rothschild; Marilyn J Manco-Johnson; Jeanne M Lusher; Elke Kellermann; Eduard Gorina; Peter J Larson
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

8.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Authors:  Jenny Goudemand; Chantal Rothschild; Virginie Demiguel; Christine Vinciguerrat; Thierry Lambert; Hervé Chambost; Annie Borel-Derlon; Ségolène Claeyssens; Yves Laurian; Thierry Calvez
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

9.  Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.

Authors:  Katharina Pfistershammer; Johannes Stöckl; Jürgen Siekmann; Peter L Turecek; Hans Peter Schwarz; Birgit M Reipert
Journal:  Thromb Haemost       Date:  2006-09       Impact factor: 5.249

Review 10.  The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.

Authors:  E D Gomperts
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287
View more
  13 in total

1.  Factor VIII inhibitor and source of replacement therapy.

Authors:  Pier Mannuccio Mannucci; Alessandro Gringeri; Elena Santagostino; Flora Peyvandi
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

2.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

Review 3.  Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Liviana Catalano; Rosa Chianese; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443

7.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

Review 8.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

Review 9.  The modern treatment of haemophilia: a narrative review.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

10.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.